Home LiteratureArticle Details
PMID: 28351561 Published · ppublish English Journal Article

Salvage surgery in recurrent head and neck squamous cell carcinoma: Oncologic outcome and predictors of disease free survival.

Oral oncology ·Vol. 67 ·2017-00-00 ·Pages 1-9

Hamoir M, Holvoet E, Ambroise J, Lengelé B, Schmitz S

Abstract

Salvage surgery in recurrent SCCHN is associated with poor outcomes. This study aimed to better identify suitable surgical candidates and those at high risk of new recurrence. Single-center retrospective analysis of 109 patients undergoing salvage surgery for recurrent SCCHN. Univariate and multivariate analyses were used to identify prognostic factors affecting disease-free survival (DFS). The following factors showed a significant impact on DFS: Disease-free interval >6months [HR 0.53; p=0.04], age>70years [HR 0.26; p=0.03], primary chemoradiotherapy [HR 2.39; p<0.01] compared to radiotherapy, oropharynx [HR 5.46; p<0.01] and hypopharynx [HR 3.92; p=<0.01] sites, compared to larynx, initial stage III [HR 7.10; p<0.01] and stage IV [HR 4.13; p<0.01], compared to stage I, locoregional recurrence [HR 4.57; p<0.01], compared to local recurrence. Univariate analysis also identified significant postoperative predictors of poor DFS including flap reconstruction [HR 3.44; p<0.01], postoperative complications [HR 2.09; p=0.01], positive margins [HR 3.64; p<0.01] and close margins [HR 3.83; p<0.01]. On multivariate analysis, oropharynx site [HR 3.98; p<0.01], initial stage III [HR 5.93; p<0.01] and locoregional recurrence [HR 2.93; p=0.04] were independent preoperative prognostic factors for DFS. Positive margins [HR 2.32; p=0.04], close margins [HR 2.94; p=0.02], extracapsular spread (ECS) [HR 4.04; p=0.03] and postoperative complications [HR 3.64; p<0.01] were independent postoperative prognostic factors. Patients with advanced primary nonlaryngeal tumor and locoregional recurrence have limited success with salvage surgery. Because patients with positive margins and ECS are at high risk of relapse, adjuvant treatment should be discussed.

Keywords
Head and neck cancer Primary treatment failure Recurrent disease Salvage surgery Squamous cell carcinoma
MeSH Terms
Adult Aged Aged, 80 and over Carcinoma, Squamous Cell/surgery Disease-Free Survival Female Head and Neck Neoplasms/surgery Humans Male Middle Aged Recurrence Salvage Therapy Squamous Cell Carcinoma of Head and Neck Treatment Outcome
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Hamoir Marc
Department of Head & Neck Surgery, St Luc University HospitaI and King Albert II Cancer Institute, Brussels, Belgium; Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium. Electronic address: marc.hamoir@uclouvain.be.
Holvoet Emma
Department of Head & Neck Surgery, St Luc University HospitaI and King Albert II Cancer Institute, Brussels, Belgium.
Ambroise Jerôme
Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium; Center for Applied Molecular Technologies (CTMA), Université Catholique de Louvain, Brussels, Belgium.
Lengelé Benoît
Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium; Department of Plastic and Reconstructive Surgery, King Albert II Cancer Institute & St Luc University Hospital, Brussels, Belgium.
Schmitz Sandra
Department of Head & Neck Surgery, St Luc University HospitaI and King Albert II Cancer Institute, Brussels, Belgium; Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium.
Article Info
Journal
Oral oncology
Abbr.
Oral Oncol
ISSN
1879-0593
Published
2017-00-00
Epub
2017-00-28
Pages
1-9
Language
English
Region
England
NLM ID
9709118
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com